The market for non-muscle invasive bladder cancer (NMIBC) reached approximately USD 3 billion in 2025, with the United States serving as the primary driver of expenditure. While traditional standards of care rely on surgical intervention and BCG immunotherapy, the surge in late-stage clinical development—including candidates like CG Oncology’s cretostimogene grenadenorepvec and enGene’s detalimogene voraplasmid—promises to redefine treatment protocols by 2036.

Physicians are increasingly prioritizing localized drug delivery systems, such as Janssen’s TAR-210, to maximize efficacy while mitigating the systemic toxicity associated with traditional approaches. Industry analysts project that the combination of cretostimogene grenadenorepvec and pembrolizumab will command a significant share of future revenue. Despite recent regulatory approvals for agents like ZUSDURI and ANKTIVA, the absence of a definitive curative therapy continues to fuel aggressive research into immunomodulators and gene-based platforms.